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Their study not only comprehensively sets the scene for neonatal sepsis and antimicrobial re sistance in a lowincome and middle-income setting but also, by highlighting gaps in our understanding of neonatal sepsis and antimicrobial resistance, sets the future research agenda.
The absence of a globally accepted single standard defi nition of multidrug resistance is a key issue.
2,3 Diffi culties in showing a clear relationship between antimicrobial resistance and outcomes might refl ect the absence of clinical relevance of currently used defi nitions. Standardised defi nitions for multidrug resistance, which account for infection type, age, and key risk factors, are now needed.
The high rates of Acinetobacter and coagulase-negative staphylococcal infections among the pathogens causing early-onset sepsis are striking, but additionally they emphasise the absence of validated defi nitions for clinical sepsis. 4 Knowledge of the clinical features and outcomes associated with such cases and their correlation with those of more established pathogens, as well as noninfected control babies, might help our understanding of their relevance and aid in validating new defi nitions.
The study 1 reported high rates of antimicrobial resistance and also reminds us of the paucity of new drugs to treat such infections, especially in neonates, as well as the paucity of data on antimicrobial pharmacokinetics in this population. Observational and interventional multicentre studies are needed to establish the safety and efficacy of new regimens and antibiotics (targeted at antimicrobialresistant pathogens) compared with existing combinations, together with new strategies for using them wisely.
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Further study in low-income and middle-income countries is required and the DeNIS collaboration is a landmark step in this direction.
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